...
首页> 外文期刊>Perspectives in Clinical Research >Up-dosing of non-sedating antihistamines in chronic urticaria: Need for well-designed clinical trials in India
【24h】

Up-dosing of non-sedating antihistamines in chronic urticaria: Need for well-designed clinical trials in India

机译:慢性荨麻疹中非镇静抗组胺药的剂量增加:印度需要精心设计的临床试验

获取原文
           

摘要

Urticaria is a heterogeneous group of diseases. Chronic urticaria significantly impacts quality-of-life of patients. Second generation, non-sedating antihistamines are recommended as first line treatment for chronic spontaneous urticaria. In patients with inadequate control of symptoms, increase in dosage of non-sedating antihistamines up to four fold has been recommended. This recommendation is based on low cost, good safety and good evidence of efficacy of non-sedating, second generation antihistamines. This article reviewed Indian data on up-dosing of antihistamines in chronic urticaria. There is a need for well-designed clinical trials with -up-dosing of individual antihistamines in Indian patients.
机译:荨麻疹是多种疾病。慢性荨麻疹严重影响患者的生活质量。推荐使用第二代非镇静抗组胺药作为慢性自发性荨麻疹的一线治疗。对于症状控制不充分的患者,建议将非镇静抗组胺药的剂量增加至四倍。此建议基于低成本,良好的安全性以及非镇静的第二代抗组胺药的有效性的充分证据。本文回顾了印度关于慢性荨麻疹中抗组胺药剂量增加的数据。需要精心设计的临床试验,以在印度患者中增加单个抗组胺药的剂量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号